

Anna L Goodman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7489016/publications.pdf>

Version: 2024-02-01

54
papers

11,670
citations

147566

31
h-index

182168

51
g-index

59
all docs

59
docs citations

59
times ranked

17470
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 167-179.	5.2	89
2	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	2.0	56
4	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
5	COVID-19 vaccine results might inform malaria vaccine strategies. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 440-441.	4.6	1
6	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
7	A multisite evaluation of antifungal use in critical care: implications for antifungal stewardship. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	0.9	1
8	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1131-1141.	4.6	99
9	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
10	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	13.9	357
11	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): updated guidelines from the UK. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlaa114.	0.9	77
12	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): updated guidelines from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1377-1378.	1.3	26
13	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
14	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
15	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
16	Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 939-949.	4.6	744
17	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV, the</i> , 2021, 8, e474-e485.	2.1	190
18	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	13.9	734

#	ARTICLE	IF	CITATIONS
19	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
20	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
21	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
22	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 1345-1347.	4.6	26
23	Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. <i>Clinical Infection in Practice</i> , 2021, 12, 100089.	0.2	11
24	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519
25	Effect of awake prone positioning in hypoxaemic adult patients with COVID-19. <i>Journal of the Intensive Care Society</i> , 2020, , 175114372096124.	1.1	6
26	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. <i>BMJ Open</i> , 2020, 10, e038847.	0.8	4
27	Experience of a novel community testing programme for COVID-19 in London: Lessons learnt. <i>Clinical Medicine</i> , 2020, 20, e165-e169.	0.8	13
28	Evaluation of Microbiological Sampling Practice in Community Acquired Pneumonia at a South London Trust: The Cheaper, the Better?. <i>Access Microbiology</i> , 2020, 2, .	0.2	0
29	Adjunctive rifampicin for <i>Staphylococcus aureus</i> bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 668-678.	6.3	140
30	Bawa-Garba case: an objective view on diagnosing group A streptococcal sepsis. <i>Clinical Medicine</i> , 2018, 18, 438-438.	0.8	0
31	Nonantibiotic prevention and management of recurrent urinary tract infection. <i>Nature Reviews Urology</i> , 2018, 15, 750-776.	1.9	155
32	Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against <i>Mycobacterium bovis</i> bacillus Calmette-Guérin challenge in mice. <i>Immunology</i> , 2015, 146, 264-270.	2.0	8
33	Preclinical Assessment of Viral Vecteded and Protein Vaccines Targeting the Duffy-Binding Protein Region II of <i>Plasmodium Vivax</i> . <i>Frontiers in Immunology</i> , 2015, 6, 348.	2.2	44
34	Pericardial mass and cardiac tamponade associated with <i>Mycoplasma pneumoniae</i> . <i>Clinical Medicine</i> , 2015, 15, 106-107.	0.8	0
35	Intractable diarrhoea despite immune reconstitution in an HIV positive man. <i>Journal of Clinical Virology</i> , 2015, 69, 219-222.	1.6	1
36	Awareness of Meningococcal Disease among Travelers from the United Kingdom to the Meningitis Belt in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 281-286.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	5.8	256
38	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, 1706.	1.6	36
39	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	1.9	194
40	T Cell Responses Induced by Adenoviral Vected Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. <i>PLoS ONE</i> , 2012, 7, e44943.	1.1	23
41	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. <i>Nature Communications</i> , 2011, 2, 601.	5.8	233
42	A Viral Vected Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity. <i>PLoS ONE</i> , 2011, 6, e29428.	1.1	56
43	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1815-1820.	1.3	80
44	Prime-boost vectored malaria vaccines: Progress and prospects. <i>Hum Vaccin</i> , 2010, 6, 78-83.	2.4	184
45	New Candidate Vaccines against Blood-Stage <i>Plasmodium falciparum</i> Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1. <i>Infection and Immunity</i> , 2010, 78, 4601-4612.	1.0	46
46	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. <i>Cell Host and Microbe</i> , 2009, 5, 95-105.	5.1	65
47	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. <i>Vaccine</i> , 2009, 27, 5589-5598.	1.7	19
48	Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008, 14, 819-821.	15.2	148
49	Tuberculosis. <i>Clinical Medicine</i> , 2008, 8, 531-534.	0.8	6
50	Central airway obstruction caused by a peripheral hamartoma. <i>Lung Cancer</i> , 2007, 57, 395-398.	0.9	6
51	Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: A randomised trial. <i>Lung Cancer</i> , 2006, 54, 51-55.	0.9	57
52	Trouble comes in twos. <i>BMJ: British Medical Journal</i> , 2005, 330, 1079.	2.4	0
53	CIGUATERA POISONING IN VANUATU. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 263-266.	0.6	10
54	Ciguatera poisoning in Vanuatu. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 263-6.	0.6	1